BO
Live price temporarily unavailable.
Price history
Bolt Biotherapeutics (BOLT) is a Health Care company. Latest news and coverage below.
IPO: February 5, 2021 · $20.00 offering · NASDAQ · View IPO details →
Bolt Biotherapeutics revenue & net income history (FY2020–FY2025)
RevenueNet income
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $231.0K | $1.26M | $5.73M | $7.88M | $7.69M | $7.70M |
| Growth (year over year) | — | +445.5% | +354.7% | +37.5% | −2.4% | +0.1% |
| Operating income | −$49.2M | −$92.8M | −$90.3M | −$76.2M | −$73.0M | −$36.1M |
| Operating margin | −21290.9% | −7364.1% | −1576.6% | −967.4% | −949.9% | −469.3% |
| Net income | −$60.7M | −$98.6M | −$88.1M | −$69.2M | −$63.1M | −$33.4M |
| Net margin | −26289.2% | −7824.7% | −1537.8% | −878.6% | −820.8% | −433.7% |
| EPS (diluted) | −$11556.00 | −$59.40 | −$47.20 | −$36.60 | −$33.06 | −$17.85 |
| Balance sheet | ||||||
| Cash and equivalents | $5.54M | $27.4M | $9.24M | $10.8M | $7.21M | $11.7M |
| Total assets | $46.5M | $307.7M | $227.8M | $159.8M | $99.6M | $56.7M |
| Total liabilities | $46.2M | $57.6M | $56.3M | $47.0M | $42.4M | $30.2M |
| Shareholders' equity | −$104.9M | $250.1M | $171.5M | $112.7M | $57.2M | $26.5M |
| Cash flow | ||||||
| Operating cash flow | −$47.3M | −$57.1M | −$76.5M | −$69.5M | −$61.3M | −$39.9M |
| Capital expenditure | $3.26M | $2.34M | $1.95M | $206.0K | $41.0K | $72.0K |
| Free cash flow | −$50.6M | −$59.4M | −$78.5M | −$69.7M | −$61.3M | −$39.9M |
RevenueNet income
| Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.14M | — | $1.22M | $1.80M | $2.17M | $2.50M | $26.0K | $5.00K |
| Growth (year over year) | −54.9% | — | −76.8% | +41.5% | +90.1% | — | −97.9% | −99.7% |
| Operating income | −$16.4M | — | −$12.1M | −$9.21M | −$7.70M | −$7.08M | −$7.60M | −$8.37M |
| Operating margin | −1441.1% | — | −991.4% | −510.5% | −355.1% | −283.4% | −29234.6% | −167480.0% |
| Net income | −$15.2M | — | −$11.0M | −$8.56M | −$7.14M | −$6.63M | −$7.24M | −$7.72M |
| Net margin | −1330.1% | — | −903.4% | −474.6% | −329.4% | −265.2% | −27861.5% | −154400.0% |
| EPS (diluted) | −$7.93 | — | −$5.76 | −$4.46 | −$3.72 | −$3.91 | −$4.31 | −$4.57 |
| Balance sheet | ||||||||
| Cash and equivalents | $9.37M | $7.21M | $8.39M | $9.60M | $17.8M | $11.7M | $11.6M | $12.9M |
| Total assets | $109.3M | $99.6M | $85.9M | $75.5M | $65.1M | $56.7M | $48.0M | $40.3M |
| Total liabilities | $37.3M | $42.4M | $39.1M | $36.7M | $33.0M | $30.2M | $28.2M | $27.7M |
| Shareholders' equity | $72.0M | $57.2M | $46.8M | $38.8M | $32.1M | $26.5M | $19.8M | $12.6M |
| Cash flow | ||||||||
| Operating cash flow | −$14.0M | — | −$13.4M | −$9.60M | −$9.73M | −$7.16M | −$8.02M | −$6.54M |
| Capital expenditure | $41.0K | — | — | — | $72.0K | $0 | — | — |
| Free cash flow | −$14.0M | — | — | — | −$9.80M | −$7.16M | — | — |
From Bolt Biotherapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Bolt Biotherapeutics
- Headquarters
- Redwood City, California From SEC filings, Oct 2026
Recent News (1)
Other Health Care companies to compare with BOLT
- BNR Burning Rock Biotech
- BNTC Benitec Biopharma Inc
- BNTX BioNTech
- BOLD Boundless Bio
- BON Bon Natural Life
- BRKR Bruker
- BTMD Biote Corp Class a
- BTSG Brightspring Health Services Inc